<DOC>
	<DOCNO>NCT00419172</DOCNO>
	<brief_summary>The study consist two open-label period , Treatment Period I ( deferasirox ) Treatment Period II ( rifampicin+deferasirox ) . At least 18 subject expect complete treatment period per protocol . For subject , addition two treatment period , 21 day screen period , one baseline evaluation ( day precede deferasirox administration Treatment Period I ) , end-of-study evaluation ( EOS ) . Study subject require remain unit Day -1 Day 17 . EOS evaluation ( final safety assessment ) perform 7-10 day last dose rifampicin .</brief_summary>
	<brief_title>Effect Potent Inducer Rifampicin Pharmacokinetics Deferasirox Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Inclusion criterion 1 . Able willing provide write informed consent prior study participation 2 . Male subject 18 45 year age good health evidence iron deficiency . Subjects reproductive potential must use barrier contraception throughout trial . 3 . Able communicate well investigator comply requirement study 4 . Subjects must body mass index ( BMI ) 18 33 . 5 . Serum ferritin value ≥20 ng/mL transferrin saturation ( Iron/TIBC ) ≥15 % screen Exclusion criterion 1 . History presence impair renal function 2 . Abnormal serum electrolyte ( e.g . sodium , potassium , chloride , bicarbonate ) , magnesium calcium 3 . Evidence urinary obstruction difficulty void screen 4 . Anemia ( define hemoglobin &lt; 13 g/dL ) 5 . A positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result screen 6 . Subjects know history HIV seropositivity history immunocompromise 7 . A past medical history ECG abnormalities family history prolong QTinterval syndrome 8 . Donation loss 400 mL blood within 12 week prior dose 9 . Smokers ( use tobacco product previous 3 month ) . * Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Deferasirox</keyword>
	<keyword>Exjade</keyword>
	<keyword>ICL670</keyword>
	<keyword>Rifampicin</keyword>
	<keyword>Healthy , Volunteers</keyword>
</DOC>